JP7560255B2 - ヘミアスタリン誘導体を含む抗体薬物複合体を含有する医薬 - Google Patents

ヘミアスタリン誘導体を含む抗体薬物複合体を含有する医薬 Download PDF

Info

Publication number
JP7560255B2
JP7560255B2 JP2020022548A JP2020022548A JP7560255B2 JP 7560255 B2 JP7560255 B2 JP 7560255B2 JP 2020022548 A JP2020022548 A JP 2020022548A JP 2020022548 A JP2020022548 A JP 2020022548A JP 7560255 B2 JP7560255 B2 JP 7560255B2
Authority
JP
Japan
Prior art keywords
formula
compound
cancer
antibody
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020022548A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020132638A (ja
JP2020132638A5 (https=
Inventor
仁志 坂
篤志 諏訪
洋輔 高梨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Pharma Co Ltd
Original Assignee
Sumitomo Dainippon Pharma Co Ltd
Sumitomo Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Dainippon Pharma Co Ltd, Sumitomo Pharma Co Ltd filed Critical Sumitomo Dainippon Pharma Co Ltd
Publication of JP2020132638A publication Critical patent/JP2020132638A/ja
Publication of JP2020132638A5 publication Critical patent/JP2020132638A5/ja
Application granted granted Critical
Publication of JP7560255B2 publication Critical patent/JP7560255B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Landscapes

  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2020022548A 2019-02-13 2020-02-13 ヘミアスタリン誘導体を含む抗体薬物複合体を含有する医薬 Active JP7560255B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019023972 2019-02-13
JP2019023972 2019-02-13

Publications (3)

Publication Number Publication Date
JP2020132638A JP2020132638A (ja) 2020-08-31
JP2020132638A5 JP2020132638A5 (https=) 2022-12-28
JP7560255B2 true JP7560255B2 (ja) 2024-10-02

Family

ID=72262311

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020022548A Active JP7560255B2 (ja) 2019-02-13 2020-02-13 ヘミアスタリン誘導体を含む抗体薬物複合体を含有する医薬

Country Status (1)

Country Link
JP (1) JP7560255B2 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115286820B (zh) * 2022-10-10 2022-12-16 佛山科学技术学院 一种光交联胶原基水凝胶及其制备方法和应用
EP4671233A1 (en) * 2023-06-29 2025-12-31 Pinotbio, Inc. NEW HEMIASTERLINE DERIVATIVE AND ITS USE

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011500725A (ja) 2007-10-19 2011-01-06 シアトル ジェネティクス，インコーポレーテッド Ｃｄ１９結合性物質およびその使用
JP2012522513A (ja) 2009-04-01 2012-09-27 ジェネンテック， インコーポレイテッド 抗ＦｃＲＨ５抗体および免疫接合体ならびに使用方法
JP2016516063A (ja) 2013-03-15 2016-06-02 ザ センター フォー ドラッグ リサーチ アンド ディベロップメント 細胞毒性及び抗有糸分裂性化合物とその使用方法
WO2016123582A1 (en) 2015-01-30 2016-08-04 Sutro Biopharma, Inc. Hemiasterlin derivatives for conjugation and therapy
JP2017506234A (ja) 2014-02-06 2017-03-02 オンコマトリックス バイオファーマ，エス．エル． 抗体−薬物複合体及び免疫毒素

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9508195D0 (en) * 1995-04-20 1995-06-07 Univ British Columbia Novel biologically active compounds and compositions,their use and derivation
WO2014057436A2 (en) * 2012-10-10 2014-04-17 Adamed Sp. Z O.O. Anticancer conjugate
WO2015151079A2 (en) * 2015-06-20 2015-10-08 Hangzhou Dac Biotech Co, Ltd Auristatin analogues and their conjugates with cell-binding molecules

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011500725A (ja) 2007-10-19 2011-01-06 シアトル ジェネティクス，インコーポレーテッド Ｃｄ１９結合性物質およびその使用
JP2012522513A (ja) 2009-04-01 2012-09-27 ジェネンテック， インコーポレイテッド 抗ＦｃＲＨ５抗体および免疫接合体ならびに使用方法
JP2016516063A (ja) 2013-03-15 2016-06-02 ザ センター フォー ドラッグ リサーチ アンド ディベロップメント 細胞毒性及び抗有糸分裂性化合物とその使用方法
JP2017506234A (ja) 2014-02-06 2017-03-02 オンコマトリックス バイオファーマ，エス．エル． 抗体−薬物複合体及び免疫毒素
WO2016123582A1 (en) 2015-01-30 2016-08-04 Sutro Biopharma, Inc. Hemiasterlin derivatives for conjugation and therapy

Also Published As

Publication number Publication date
JP2020132638A (ja) 2020-08-31

Similar Documents

Publication Publication Date Title
JP7623413B2 (ja) ヘミアスタリン誘導体を含む抗体薬物複合体
JP7605809B2 (ja) ヘミアスタリン誘導体及びこれらの抗体薬物複合体
US12178879B2 (en) Hemiasterlin derivative and antibody-drug conjugate thereof
JP7560255B2 (ja) ヘミアスタリン誘導体を含む抗体薬物複合体を含有する医薬
JP7432531B2 (ja) システイン残基を有するヘミアスタリン誘導体
HK40104461A (en) Hemiasterlin derivatives and antibody-drug conjugates including same
HK40028211A (en) Antibody-drug conjugates including hemiasterlin derivative
HK40028211B (en) Antibody-drug conjugates including hemiasterlin derivative
HK40065482A (en) Hemiasterlin derivative having cysteine residue
HK40028206A (en) Hemiasterlin derivatives and antibody-drug conjugates including same

Legal Events

Date Code Title Description
AA64 Notification of invalidation of claim of internal priority (with term)

Free format text: JAPANESE INTERMEDIATE CODE: A241764

Effective date: 20200310

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200304

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221220

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221220

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230919

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230919

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240115

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240416

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240917

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240919

R150 Certificate of patent or registration of utility model

Ref document number: 7560255

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150